Trials / Unknown
UnknownNCT04598984
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Istanbul Training and Research Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | serum adipokines | Level of serum adipokines will be measured with flow cytometry |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2022-12-30
- Completion
- 2022-12-31
- First posted
- 2020-10-22
- Last updated
- 2022-08-08
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT04598984. Inclusion in this directory is not an endorsement.